64532-22-5

Usage

Uses

Used in Pharmaceutical Synthesis:
6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its unique structure allows it to be a building block in the creation of various medicinal compounds.
Used in Organic Chemistry Research:
In the field of organic chemistry, 6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER serves as a research chemical, facilitating the study of organic reactions and the exploration of new synthetic pathways. Its properties make it a valuable tool for scientists in understanding and advancing chemical knowledge.
Used in Drug Development:
6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER is utilized in the development of new drugs, particularly in the area of oncology, due to its relationship with the anti-cancer drug, tegafur. Its potential role in drug discovery highlights its importance in medicinal chemistry.
Used in the Laboratory:
6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER is used as a reagent in laboratory settings where its properties are harnessed for various chemical reactions and experiments. It is essential to handle this chemical with care and follow appropriate safety precautions to ensure a safe working environment.

InChI:InChI=1/C7H8N2O3/c1-4-8-5(7(11)12-2)3-6(10)9-4/h3H,1-2H3,(H,8,9,10)

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 17551-52-9 2-methyl-4-hydroxy-6-chloropyrimidine 
• 1780-26-3 2,4-dichloro-2-methylpyrimidine 

Downstream Products

• 1112178-37-6 N-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide 
• 1112178-44-5 N-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide 
• 1112169-64-8 N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide 
• 1112169-66-0 N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide 
• 1112170-12-3 (2S,5S)-5-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)-1,4-dioxane-2-carboxylic acid 

Relevant academic research and scientific papers

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.